Therapy Areas: Cardiovascular
Dr. Reddy's Laboratories Launches Lansoprazole DR Orally Disintegrating Tablets in the US Market
23 February 2021 - - Indian pharmaceutical company Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) (NSEIFSC: DRREDDY) has launched Lansoprazole DR Orally Disintegrating Tablets, a therapeutic equivalent generic version of Prevacid SoluTab Delayed-Release Orally Disintegrating Tablets, 15 mg and 30 mg, approved by the US Food and Drug Administration (USFDA), the company said.

The Prevacid brand and generic had US sales of approximately USD 87m MAT for the most recent twelve months ending in December 2020 according to IMS Health.

Dr. Reddy's Lansoprazole DR Orally Disintegrating Tablets are available in 15 mg and 30 mg tablets in unit-dose packages of 100 (10 x 10).

The company works through its three businesses Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products.

Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. its major markets include USA, India, Russia and CIS countries, and Europe.
Login
Username:

Password:


Related Headlines